MJBizDaily’s recent piece argues that the cannabis industry must give genetics a strategic role beyond marketing. For breeders, seedbanks and commercial growers that means clear provenance, investment in breeding and data, and active stewardship to protect diversity, IP and supply resilience. This editorial explains what the argument means in practical terms for professionals and where the industry will need attention next.

The Psychiatric Times argues that cannabis policy affects psychiatric outcomes in ways that go beyond simple legality. This editorial unpacks the policy levers at work, who in the sector should take notice and what practical steps regulators, clinicians and industry actors can reasonably expect or demand next.

MJBizDaily has highlighted a simple proposition: genetics are the cannabis industry’s most valuable asset. For breeders, seedbanks, producers and distributors that claim to sell consistency, potency or therapeutic value, that statement should change how contracts, quality assurance and corporate strategy are organised.